The acquisition is anticipated to bolster Mankind Pharma’s position in the Indian women’s health and fertility drug market. Credit: fizkes / Shutterstock.

Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn) deal.

The move bolsters Mankind Pharma’s position in the Indian women’s health and fertility drug market.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The deal will also aid Mankind Pharma in providing access to high-barrier products in critical care leveraging complex research and development (R&D) tech platforms.

BSV, with more than five decades of expertise in biopharmaceuticals, has an established presence with its in-house developed recombinant and niche biologic products.

The company’s branded product portfolio spans women’s health, fertility and critical care, with several leading brands in their respective therapy areas.

Mankind Pharma vice-chairman and managing director Rajeev Juneja stated: “BSV’s acquisition represents a pivotal milestone in Mankind’s journey, establishing us as a market leader in the Indian women’s health and fertility segment. We believe the women’s health and fertility segment has massive opportunity along with strong growth visibility globally, led by structural tailwinds.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“BSV’s established speciality R&D tech platforms with a complex portfolio across women’s health, fertility, critical care and [the] immunoglobulin segment perfectly aligns Mankind Pharma’s strategic vision to expand its footprint in high entry barrier portfolio. We are also delighted to welcome BSV’s 2,500+ members to our Mankind family.”

The acquisition includes BSV’s comprehensive portfolio in women’s health, covering the reproductive lifecycle from fertility to post-pregnancy.

Its significant portfolio in the fertility segment will aid in scaling in both Indian and international markets, especially with the increasing penetration of in vitro fertilisation (IVF) treatments.

Mankind Pharma CEO and whole-time director Sheetal Arora stated: “Mankind’s strategic acquisition of BSV with branded speciality pharma portfolio across India and emerging markets presents immense growth potential and will add to the existing growth velocity of Mankind.”